Roche announced this week that its bladder cancer treatment, Tecentriq, has won FDA approval to treat advanced bladder cancer. The advanced approval decision makes Tecentriq the first pharmaceutical to be used as a first-line treatment of advanced bladder cancer. Tecentriq was the first drug to be approved in the treatment of bladder cancer. Roche is currently one of three companies testing approved bladder cancer treatment for other cancer therapies. Read the full article here.